Neil Cohen - 16 Mar 2023 Form 4 Insider Report for Chemomab Therapeutics Ltd. (CMMB)

Role
Director
Signature
/s/ Neil Cohen
Issuer symbol
CMMB
Transactions as of
16 Mar 2023
Net transactions value
$0
Form type
4
Filing time
23 Mar 2023, 07:35:31 UTC
Previous filing
18 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CMMB American Depositary Shares 10,000 16 Mar 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMMB Option to Purchase American Depositary Shares Award $0 +6,875 $0.000000 6,875 16 Mar 2023 American Depositary Shares 6,875 $1.62 Direct F1, F3
transaction CMMB Option to Purchase American Depositary Shares Award $0 +6,820 $0.000000 6,820 07 Mar 2022 American Depositary Shares 6,820 $3.53 Direct F1, F2, F4
transaction CMMB Option to Purchase American Depositary Shares Award $0 +11,884 $0.000000 11,884 19 Apr 2021 American Depositary Shares 11,884 $27.26 Direct F1, F2, F5
transaction CMMB Option to Purchase American Depositary Shares Award $0 +688 $0.000000 688 16 Mar 2021 American Depositary Shares 688 $13.17 Direct F1, F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
F2 No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
F3 These options were granted as per the annual grant of options to directors. Those options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.
F4 These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors
F5 These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
F6 These options vest and become exercisable as follows: 1/3 vested on July 16, 2021, and the remaining options vest on a quarterly basis for the following eight quarters, subject to the Reporting Person's continued service.